Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Oculis Holding AGNASDAQ: OCS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of CHF 5M rose 90.2% year over year, ahead of the +63.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 16.0% from the prior quarter. Over 3 fiscal years it compounded at +171.2% a year.

Context

  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +90.2% holds above the trailing-twelve-month pace of +63.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 5M+16.0% QoQ
Last fiscal yearDec 2025
CHF 16.04M+64.0% YoY
LTMMar 2026
CHF 18.42M+63.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+90.2%——
1 year+64.0%——
3-year CAGR+171.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

CHF · from the cash flow

Latest · FY2025
16.04M CHF
Year-over-year change
+64.0%
4-year CAGR
+164.5%

Stock-Based Compensation vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +63.4% is the highest of 6, against a peer median of -34.4%.
  • Stock-based compensation amounts to 3653.8% of revenue for OCS, versus a peer median of 254.5%.
OCS Competitors
Stock-Based Compensation for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OCULOcular Therapeutix, Inc.LTM Mar 2026$48.31M USD+35.8%+36.5%92.8%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$31.69M USD-0.5%+25.3%416.2%
OCSOculis Holding AGLTM Mar 2026CHF 18.42M CHF+63.4%+171.2%3653.8%
HROWHarrow Health, Inc.LTM Mar 2026$11.78M USD-34.6%+16.2%4.4%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$5.14M USD-37.3%+4.9%1543.3%
OKYOOKYO Pharma LimitedFY2025$734.99K USD-34.4%-24.7%—
Peer median (excluding OCS) —-34.4%+16.2%254.5%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.52M)(38.64M)(88.7M)(85.94M)(94.51M)
Depreciation & Amortization235K299K287K406K546K
Deferred Income Tax00000
Stock-Based Compensation328K804K3.61M9.78M16.04M
Change in Working Capital(791K)6M(12.99M)14.16M(70.67K)
Accounts Receivables233K(152K)36K247K1.9M
Inventory00000
Accounts Payables30K3.04M3.73M(1.71M)(1.86M)
Other Working Capital(1.05M)3.11M(16.76M)15.62M(106.97K)
Other Non-Cash Items4.93M6.47M43.95M14.09M15.77M
Operating Cash Flow(13.83M)(25.07M)(53.85M)(47.5M)(62.22M)
Capital Expenditures(28K)(3.55M)(48K)(230K)(287.47K)
Acquisitions (Net)00000
Purchases of Investments00(54.16M)(17.33M)(58.05M)
Sales of Investments00000
Other Investing Activities0(3.48M)000
Investing Cash Flow(28K)(3.55M)(54.21M)(17.56M)(59.38M)
Debt Repayment(98K)(159K)(158K)(274K)(373K)
Common Stock Issued00135.62M53.54M178.95M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(804K)(157K)(5.79M)763K16.77K
Financing Cash Flow55.19M1.71M129.67M54.03M178.6M
Effect of Forex Changes(16K)418K(3.08M)407K174.39K
Net Change in Cash41.33M(26.49M)18.54M(10.62M)57.17M
Free Cash Flow(13.85M)(28.62M)(53.89M)(47.73M)(62.51M)

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.